MedPath

Canadian COVID-19 Emergency Department Registry

Conditions
Covid-19
Registration Number
NCT04702945
Lead Sponsor
University of British Columbia
Brief Summary

Coronavirus Disease 2019 (COVID -19) is the largest public health crisis in over a century. There is an urgent need for high-quality population-level data to understand modifiable risks for disease severity, transmissibility, and to develop evidence-based prevention (i.e. vaccination), treatment and resource allocation strategies.

The Canadian COVID-19 Emergency Department Rapid Response Network (CCEDRRN) created a population-based registry of suspected and confirmed consecutive cases of COVID-19. The purpose of this registry is to derive and validate clinical decision rules, evaluate diagnostic tests and vaccine effectiveness, and complete cohort, case-control and observational studies to inform the pandemic response.

Detailed Description

This national multi-centre registry is designed to enroll population-based consecutive eligible patients presenting with suspected or confirmed COVID-19 to 50 emergency departments in eight Canadian provinces from March 1 2020 and data collection is ongoing for the duration of the pandemic.

Data will be abstracted from the medical chart and entered into a central, web-based REDCap database. The investigators adopted the ISARIC variables into the database where there was a match. The investigators will develop standardized operating procedures for screening of potentially eligible patients, data entry and follow-up. Current data dictionaries are kept on the registry's website (https://canadiancovid19registry.org/).

At 30 days, the investigators will contact patients by telephone to obtain verbal consent for follow-up. The investigators will measure the Veterans Rand 12-item Health Survey (VR12), calculate the WHO Ordinal Outcome Scale and ask contextual questions in consenting patients. The VR12 will be measured at 60 days, and 6 and 12 months. The contextual questions were developed with input from patients with lived experience with COVID-19 infection and addressed cultural, racial, gender, socioeconomic and self-isolation issues.

The Health Data Research Network facilitated the development of a unique data flow of personal health identifiers and study identification numbers from each province for all participating institutes. This will allow linkage of registry data with national administrative data repositories.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
200000
Inclusion Criteria
  • Meeting the WHO suspect COVID-19 criteria: Fever (self-reported or subjective fever) and at least one symptom/sign of respiratory illness (e.g., flu-like illness, cough, shortness of breath)
  • Presenting to the emergency department and tested for COVID-19 in the emergency department

No exclusion criteria in Period 1

Period 2 started on the date which each province expanded testing criteria allowing clinicians to test patients based on clinical suspicion or policy.

Inclusion Criteria:

  • Presenting to the emergency department within 14 days of a positive COVID-19 (by self-report or in medical chart) and presents with clinical symptoms consistent with COVID-19
  • Tested for COVID-19 in the emergency department, or within 24 hours after emergency department arrival.

Exclusion Criteria

  • Patients tested for COVID-19 in the context of an elective admission (e.g., planned hip revision)
  • Patients tested for COVID-19 and seen in the emergency department directly by another service (e.g., trauma team activation)
Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Confirmed COVID-19 diagnosis14 days

Biological specimen is tested positive for SARS-CoV-2 using reverse transcription polymerase chain reaction (RT PCR). The specimen had to be drawn within two weeks of the emergency department visit if the patient presented with a COVID-19-related complication. If the initial test was negative, the patient had to have a positive specimen within 14 days of the index visit.

Secondary Outcome Measures
NameTimeMethod
Hospital admission30 days

Any hospital admission within 30 days of index emergency department visit captured in medical chart.

Hospital re-admissions30 days

Any hospital re-admissions within 30 days of index emergency department visit date captured in medical chart.

Mechanical ventilation30 days

Any mechanical ventilation during any hospital visit within 30 days of index emergency department visit captured in medical chart.

Emergency department revisits30 days

Any emergency department revisits within 30 days of index emergency department visit captured in medical chart.

30 day mortality30 days

Any death captured within 30 days of index emergency department visit captured by medical charts.

Clinical recovery30 days

Captured through telephone follow-up using the World Health Organization Ordinal Outcome Scale at 30 days after index emergency department visit. The scale is scored from 1 to 8 ('1'= no limitations to activities, '8'=death) to measure clinical improvement at 30 days.

Patient quality of life12 months

Captured through telephone follow-up using the Veterans Rand 12-item Health Survey at 30 days, 60 days, and 6 and 12 months after index emergency department visit.

Trial Locations

Locations (50)

Foothills Medical Centre

🇨🇦

Calgary, Alberta, Canada

Peter Lougheed Centre

🇨🇦

Calgary, Alberta, Canada

Rockyview General Hospital

🇨🇦

Calgary, Alberta, Canada

South Health Campus

🇨🇦

Calgary, Alberta, Canada

Northeast Community Health Centre

🇨🇦

Edmonton, Alberta, Canada

Royal Alexandra Hospital

🇨🇦

Edmonton, Alberta, Canada

University of Alberta Hospital

🇨🇦

Edmonton, Alberta, Canada

Abbotsford Regional Hospital

🇨🇦

Abbotsford, British Columbia, Canada

Royal Inland Hospital

🇨🇦

Kamloops, British Columbia, Canada

Kelowna General Hospital

🇨🇦

Kelowna, British Columbia, Canada

Scroll for more (40 remaining)
Foothills Medical Centre
🇨🇦Calgary, Alberta, Canada

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.